Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,473 total articles
TG Therapeutics' BRIUMVI has turned revenue momentum into higher guidance and market attention. At a market cap near $8.3B and a P/E around 19.8, the stock already prices growth; still, accelerating sales, favorable technicals and elevated short interest make a mid-term long trade compelling for disciplined traders. This idea lays out entry, stop a…
Meta is a cash-generative, high-ROE platform trading at a mid-20s earnings multiple and sitting well below its 52-week high. With hyperscaler AI spending accelerating and large investors adding to positions, we upgrade Meta to a buy and lay out a swing trade with strict risk controls: entry $552.95, stop $520, target $650.
OPENLANE (OPLN) checks the boxes for an event-driven long: improving top-line momentum, positive 2026 guidance, healthy free cash flow ($218.6M), and a valuation that could re-rate if private equity or strategic buyers pursue an exit. Enter $33.00, stop $29.00, target $44.00; horizon: long term (180 trading days).
Quantum Computing Inc. (QUBT) has shown fresh signs of commercial traction and sector momentum. The stock is trading at $8.92 with a $2.02B market cap despite razor-thin reported revenue implied by a price-to-sales of 205.52 and negative free cash flow. Given accelerating volume, heavy short interest and dated volatility, a disciplined long swing c…
Gen Digital (GEN) trades near $29 with a $17.3B market cap, attractive free cash flow and guidance that implies sustained organic growth. The stock looks cheap relative to cash generation and recent revenue momentum; this trade idea lays out a position plan with explicit entry, stop and target and the fundamental reasons to own while flagging capit…
Applied Materials (AMAT) sits at the center of the AI hardware boom. With management guiding double-digit revenue growth, a healthy balance sheet, strong free cash flow, and secular demand for semiconductor capacity, I am reiterating a Strong Buy. Trade plan: enter at current levels, stop below $450, target $620 over a 180-trading-day horizon, with…
Microsoft's scale in cloud and Copilot-driven revenue gives the company clearer near-term revenue visibility while its low leverage and large free cash flow suggest capex for AI can be funded without balance-sheet stress. This trade idea proposes a mid-term long on MSFT to capture re-rating as the market prices in sustained Azure/Copilot monetizati…
Marcus Corporation has momentum from a robust theatrical recovery, improving fundamentals, and attractive enterprise multiples. We lay out a mid-term swing trade with precise entry, stop and target, and the key catalysts and risks that will move the tape.
Gen Digital (GEN) reported a robust Q3 with revenue up 26% and raised FY26 guidance. At a $17.3B market cap and trading near $29, the stock screens cheap relative to a fast-growing subscription business and $1.55B in free cash flow. This trade idea buys that re-rating into improving fundamentals, while respecting balance-sheet and short-interest ri…
Flex Ltd. ($FLEX) is positioned to benefit from rising AI infrastructure demand through its Cloud and Power Infrastructure (CPI) and related segments. At ~$110.63, the stock offers an asymmetric setup: secular tailwinds, positive free cash flow, and a sub-2x EV/sales multiple against a hefty P/E that discounts future margin expansion. This trade id…
NextDecade (NEXT) is a pre-revenue LNG developer whose real bull case today is not tidy free cash flow but a rising base of strategic owners and insider conviction that can compress valuation ahead of cash generation. With a market cap near $1.9B, an enterprise value north of $12B, and a recurring cadence of strategic purchases and supplier wins, N…
Centene (CNC) is showing tangible margin recovery backed by outsized free cash flow, a cheap valuation (EV/EBITDA ~5.3, P/FCF ~3.6) and a management focus on profitability. This trade idea outlines a tactical long with entry, stop and targets and explains the key catalysts and risks investors should watch over the next 180 trading days.
Broadcom (AVGO) looks expensive on headline multiples, but the market is conflating near-term macro noise with structural strength in semiconductors and infrastructure software. At $368.45 we see an asymmetric trade: durable free cash flow of $32.8B, industry-leading margins and customer stickiness create a path to low-double-digit upside while dow…
Neurocrine (NBIX) offers a pragmatic entry after recent weakness: established cash-generative franchises, a recent rare-disease acquisition, and an active clinical calendar create multiple value drivers. The technicals are beatable and the balance sheet supports near-term dealmaking and buybacks. Trade plan targets a mid-term rebound while limiting…
We upgrade General Dynamics (GD) to Buy. The stock trades at roughly 23x earnings and 16x free cash flow - levels that understate the company's cash generation, low leverage and government-driven backlog growth. Combine that with recent industry financing initiatives and large shipbuilding awards, and the risk/reward favors a mid-term long trade wi…
KORU Medical (KRMD) has fallen back to near-term support after a multi-month downtrend, leaving the shares oversold and cheap relative to recent upside expectations. The company has a working infusion-delivery platform, modest leverage, and a history of revenue beats. This trade idea lays out an actionable long-swing entry at $3.20 with a $4.50 tar…
Equifax is trading like a mature credit-data vendor, yet its recurring identity and workforce businesses, strong free cash flow, and secular tailwinds in identity verification argue for a higher multiple. This trade idea takes a constructive long stance with clearly defined entry, stop and target levels and a 180-trading-day horizon.
Medtronic (MDT) trades at roughly $93 and appears materially mispriced vs. peers if its CAS (advanced surgical automation/robotics) rollout gains traction. With a $119B market cap, healthy FCF ($5.43B), a 3.1% dividend yield, and manageable leverage (debt/equity ~0.57), the balance sheet supports a buy-and-hold into execution. Entry $93.00, stop $8…
Eli Lilly is trading with strong momentum after robust GLP-1 sales and pipeline news, but new oral pills from competitors could create headline-driven volatility. We propose a mid-term long on LLY with a defined entry, stop and target while outlining catalysts and risks tied to competition from Novo Nordisk and others.
Evercore (EVR) looks positioned to benefit from elevated M&A activity through 2027. Strong free cash flow, a sub-15x P/E on documented EPS, and a capital-light balance sheet support a constructive trade. Technicals show recent weakness, offering a disciplined entry for a long-term trade into year-end.
Taylor Devices reported a weak quarter that disappointed the market, yet the company's pristine balance sheet, positive cash flow and accelerating technicals create a compelling risk/reward for a mid-term long trade. Entry at today's price captures momentum while a tight stop limits downside; target reflects a retest of higher multi-month resistanc…
ProQR is a clinical-stage RNA therapeutics company centered on its Axiomer ADAR-mediated RNA editing platform. With a market cap near $322M, a runway into mid-2027, and multiple anticipated clinical and corporate milestones, PRQR is a high-risk/high-reward buy. Entry near $2.34, stop at $1.60, primary target $4.50 (long-term), with an intermediate …
Flowers Foods (FLO) looks oversold relative to its cash-flow profile. At roughly $7 a share, the company trades with an enterprise value of ~$3.22B and generated about $296M in free cash flow, implying a low multiple and a material upside if volumes stabilize and the dividend reset funds deleveraging. This is a mid-term (45 trading days) trade idea…
Valor Gold looks fairly priced today for a junior gold explorer. The company has promising geology but needs time, financing and positive drill results to shift the market's view. This trade is a cautious long with a long-term horizon and tight risk controls.
Rapport Therapeutics is positioned to build a differentiated epilepsy franchise around RAP-219. A long apparent half-life supports sustained AMPA receptor occupancy, which could translate to durable seizure control with a favorable tolerability profile. With a market cap near $2.3B, no debt, and roughly $100M+ in cash after a 2025 financing, the se…
